Undecimal Bio: Venture Capital Funding History

Undecimal Bio is a platform biotechnology company working to revolutionize the delivery of siRNA therapeutics. Harnessing combinatorial chemistry and agentic AI through its DELiveri® technology, Undecimal identifies targeting conjugates that direct RNA medicines to cell types beyond the liver, with an initial focus on renovascular disease. Founded by Dr. Yaniv Erlich and Shaul Ilan as a spin-out of Eleven Therapeutics, the Company operates in Tel Aviv, Israel and Cambridge, UK.